These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 26942019)

  • 1. Bortezomib-Induced Complete Heart Block and Myocardial Scar: The Potential Role of Cardiac Biomarkers in Monitoring Cardiotoxicity.
    Diwadkar S; Patel AA; Fradley MG
    Case Rep Cardiol; 2016; 2016():3456287. PubMed ID: 26942019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bortezomib-based Chemotherapy for Multiple Myeloma Patients Without Comorbid Cardiovascular Disease Shows No Cardiotoxicity.
    Heitner SB; Minnier J; Naher A; Van Woerkom RC; Ritts A; Ferencik M; Broberg C; Medvedova E; Silbermann R; Scott EC
    Clin Lymphoma Myeloma Leuk; 2018 Dec; 18(12):796-802. PubMed ID: 30217616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Partially reversible bortezomib-induced cardiotoxicity: an unusual cause of acute cardiomyopathy.
    Meseeha MG; Kolade VO; Attia MN
    J Community Hosp Intern Med Perspect; 2015; 5(6):28982. PubMed ID: 26653686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Arginase Inhibition Mitigates Bortezomib-Exacerbated Cardiotoxicity in Multiple Myeloma.
    Paterek A; Oknińska M; Pilch Z; Sosnowska A; Ramji K; Mackiewicz U; Golab J; Nowis D; Mączewski M
    Cancers (Basel); 2023 Apr; 15(7):. PubMed ID: 37046852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bortezomib-induced Severe Congestive Heart Failure.
    Jerkins JH; Suciu A; Mazimba S; Calvo A
    Cardiol Res; 2010 Dec; 1(1):20-23. PubMed ID: 28352372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bortezomib-Induced Cardiac Tamponade in a 49-Year-Old Man.
    Burkhart T; Keith MCL; Lenneman CAG; Fernando RR
    Tex Heart Inst J; 2018 Aug; 45(4):260-263. PubMed ID: 30374242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heart failure secondary to carfilzomib-induced heart block in multiple myeloma patients.
    Tjionas H; Gupta AK
    J Oncol Pharm Pract; 2017 Mar; 23(2):152-156. PubMed ID: 26786028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severe heart failure after bortezomib treatment in a patient with multiple myeloma: a case report and review of the literature.
    Bockorny M; Chakravarty S; Schulman P; Bockorny B; Bona R
    Acta Haematol; 2012; 128(4):244-7. PubMed ID: 22964848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteasome inhibitors in the treatment of B-cell malignancies.
    Schenkein D
    Clin Lymphoma; 2002 Jun; 3(1):49-55. PubMed ID: 12141956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanistic rationale and clinical evidence for the efficacy of proteasome inhibitors against indolent and mantle cell lymphomas.
    Paoluzzi L; O'Connor OA
    BioDrugs; 2006; 20(1):13-23. PubMed ID: 16573348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of Cardiovascular Toxicity Associated with Treatments Containing Proteasome Inhibitors in Multiple Myeloma Therapy.
    Iannaccone A; Bruno G; Ravera A; Gay F; Salvini M; Bringhen S; Sabia L; Avenatti E; Veglio F; Milan A
    High Blood Press Cardiovasc Prev; 2018 Jun; 25(2):209-218. PubMed ID: 29582365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiotoxicity associated with bortezomib: A single-center experience.
    Gurram MK; Pulivarthi S; Ehresmann K; Mathew J
    J Cancer Res Ther; 2017; 13(6):961-963. PubMed ID: 29237959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Left atrial and ventricular epicardial dual chamber pacing through a left lateral thoracotomy to treat pediatric complete atrioventricular block].
    Li XM; Zhang Y; Pan GY; Liu HJ; Li HY; Wu QY
    Zhonghua Er Ke Za Zhi; 2013 Aug; 51(8):578-83. PubMed ID: 24225287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patterns of cardiac toxicity associated with irreversible proteasome inhibition in the treatment of multiple myeloma.
    Grandin EW; Ky B; Cornell RF; Carver J; Lenihan DJ
    J Card Fail; 2015 Feb; 21(2):138-44. PubMed ID: 25433360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I trial of palbociclib plus bortezomib in previously treated mantle cell lymphoma.
    Martin P; Ruan J; Furman R; Rutherford S; Allan J; Chen Z; Huang X; DiLiberto M; Chen-Kiang S; Leonard JP
    Leuk Lymphoma; 2019 Dec; 60(12):2917-2921. PubMed ID: 31120355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular Complications of Proteasome Inhibitors Used in Multiple Myeloma.
    Cole DC; Frishman WH
    Cardiol Rev; 2018; 26(3):122-129. PubMed ID: 29077585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complete heart block secondary to bortezomib use in multiple myeloma.
    Dasanu CA
    J Oncol Pharm Pract; 2011 Sep; 17(3):282-4. PubMed ID: 20406745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Marked clinical activity of the proteasome inhibitor bortezomib in patients with follicular and mantle-cell lymphoma.
    O'Connor OA
    Clin Lymphoma Myeloma; 2005 Nov; 6(3):191-9. PubMed ID: 16354324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early Steps in Herpes Simplex Virus Infection Blocked by a Proteasome Inhibitor.
    Schneider SM; Pritchard SM; Wudiri GA; Trammell CE; Nicola AV
    mBio; 2019 May; 10(3):. PubMed ID: 31088925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DANFIN functions as an inhibitor of transcription factor NF-κB and potentiates the antitumor effect of bortezomib in multiple myeloma.
    Uematsu A; Kido K; Manabe E; Takeda H; Takahashi H; Hayashi M; Imai Y; Sawasaki T
    Biochem Biophys Res Commun; 2018 Jan; 495(3):2289-2295. PubMed ID: 29284118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.